The Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing City, Jiangsu Province, China.
J Ovarian Res. 2024 Oct 4;17(1):196. doi: 10.1186/s13048-024-01523-z.
Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), treatment options are limited, and their survival prospects are grim. The emergence of antibody-drug conjugates (ADCs) shows promises as a future treatment for PROC. This review synthesizes current research on the effectiveness of ADCs in treating PROC. It encapsulates the advancements and clinical trials of novel ADCs that target specific antigens such as Folate Receptor alpha (FRα), MUC16, NaPi2b, Mesothelin, Dipeptidase 3(DPEP3), and human epidermal growth factor receptor 2 (HER2), as well as tissue factor, highlighting their potential anti-tumor efficacy and used in combination with other therapies. The ADCs landscape in ovarian cancer therapeutics is swiftly evolving, promising more potent and efficacious treatment avenues.
铂类是卵巢癌全身治疗的关键组成部分。然而，大多数患者最终会面临复发，导致化疗耐药，尤其是对铂类耐药。对于铂耐药性卵巢癌（PROC）患者，治疗选择有限，生存前景严峻。抗体药物偶联物（ADC）的出现为 PROC 的未来治疗带来了希望。本综述综合了 ADC 治疗 PROC 的有效性的当前研究。它概述了针对特定抗原（如叶酸受体α（FRα）、MUC16、NaPi2b、间皮素、二肽酶 3（DPEP3）和人表皮生长因子受体 2（HER2））以及组织因子的新型 ADC 的进展和临床试验，强调了它们的潜在抗肿瘤疗效，并与其他疗法联合使用。ADC 在卵巢癌治疗领域的发展迅速，有望为治疗提供更有效和更有效的途径。
